The blockade of THBS1-dependent TGF-β activity has been discovered to reduce proteinuria and improve markers of tubulointerstitial injury (fibronectin) in a murine model of diabetic nephropathy (Lu et al., 2011). Here, FN1 is linked to diabetic kidney disease.